Custom synthesis | Naphthyridine | Pyrimidine | Indoline |
New Melocules

936563-96-1 Ibrutinib

Ibrutinib (also known as PCI-32765 and marketed under the name Imbruvica) is an anticancer drug targeting B-cell malignancies. It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase (BTK).

It was approved by the US Food and Drug Administration (FDA) in November 2013 for the treatment of mantle cell lymphoma and in February 2014 for the treatment of chronic lymphocytic leukemia. In January 2015, ibrutinib was approved by the FDA for treatment of Waldenström's macroglobulinemia, a form of non-Hogkins lymphoma. According to the Wall Street Journal by January 2016 isbrutinib, a specialty drug, cost US$116,600 to $155,400 a year wholesale in the United States. In spite of discounts and medical insurance, the prohibitive price causes some patients to not fill their prescriptions. The company marketing the drug, AbbVie, did not develop the drug but acquired it through an acquisition in May 2015. AbbVie estimates global sales of the drug at $1 billion in 2016 and $5 billion in 2020.

936563-96-1 Ibrutinib
Ibrutinib 936563-96-1
Appearance:White Solid
Cas No: 1405-87-4
EINECS:NA
Formula:C25H24N6O2
Molecular Weight:440.50
Melting Point:NA
Boiling Point:715°C
Flash Point: 386.2°C
Usage:antineoplastics
Testing Items
Standards:Enterprise
Appearance
White to off white solid
Identification
should conform
Purity NLT98%

Disclaimer:Those products (936563-96-1 Ibrutinib) patented are for lab analytical & research purposes only.